Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cytisinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 12/20 | 0.97 |
| ▸ | CHRNA4 known ✓ | P43681 | 12/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.97 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.97 |
| ▸ | CHRNG | P07510 | 4/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.97 |
| ▸ | CHRND | Q07001 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytisinicline SCHEMBL1500421 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL14870500 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL161398 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL8309064 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL13595657 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL472026 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL19877933 | 0.97 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL1500403 | 0.92 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL20680760 | 0.89 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL19209244 | 0.88 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529924-B1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING CYTISINE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025068549-A1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING CYTISINE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-03 | — | — | WO | disclosed |
| EP-4529924-A1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING CYTISINE | LTS Lohmann Therapie-Systeme AG (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-20240287073-A1 | 4-SUBSTITUED CYTISINE ANALOGUES | THE UNIVERSITY OF BRISTOL (GB) | 2024-08-29 | — | — | US | disclosed |
| US-11905287-B2 | 4-substitued cytisine analogues | THE UNIVERSITY OF BRISTOL (GB) | 2024-02-20 | — | — | US | disclosed |
| US-20230203038-A1 | 4-SUBSTITUED CYTISINE ANALOGUES | THE UNIVERSITY OF BRISTOL (GB) | 2023-06-29 | — | — | US | disclosed |
| US-11667638-B2 | 4-substitued cytisine analogues | THE UNIVERSITY OF BRISTOL | 2023-06-06 | — | — | US | disclosed |
| EP-4112620-A1 | CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION | The University of Bristol (GB) | 2023-01-04 | — | — | EP | disclosed |
| EP-3500572-B1 | CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION | UNIV BRISTOL (GB) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667638-B2 | 4-substitued cytisine analogues | CES2, CDA, PCYT1A | CHRNB2 48/4885CHRNA4 7/4885CHRNB4 21/4885 |
| US-20230203038-A1 | 4-SUBSTITUED CYTISINE ANALOGUES | CES2, CDA, PCYT1A | CHRNB2 48/4885CHRNA4 7/4885CHRNB4 21/4885 |
| US-20240287073-A1 | 4-SUBSTITUED CYTISINE ANALOGUES | CES2, CDA, PCYT1A | CHRNB2 48/4885CHRNA4 7/4885CHRNB4 21/4885 |
| US-11905287-B2 | 4-substitued cytisine analogues | CES2, CDA, PCYT1A | CHRNB2 48/4885CHRNA4 7/4885CHRNB4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.